71-OR: Youth with Type 1 Diabetes and Their Parents Report Improved Quality of Life with the Omnipod 5 Automated Insulin Delivery System

Type 1 diabetes (T1D) can lead to significant emotional distress and impair quality of life (QoL). Hybrid closed-loop (HCL) technology seeks to relieve this burden, a goal with equal importance to improving glycemic outcomes. We evaluated change in QoL outcomes for children (6.0-11.9y) and teens (12.0-17.9y) with T1D and their parents/guardians before and after a 3-month study of HCL therapy with the Omnipod 5 System. Validated assessment tools administered included diabetes-related QoL (PAID and HCS) and generic QoL (PSQI and WHO-5) questionnaires. Children (n=83) and teens (n=42) were (mean±SD): age 9±2y and 14±2y, with T1D duration 4±2y and 7±3y and A1C 7.5±0.9% and 7.9±1.0%, respectively. Responses revealed significantly reduced diabetes distress for all groups (Table). Also, parents of children reported significant improvement in overall well-being (WHO-5), hypoglycemic confidence (HCS) and in 3 PSQI sleep subscales: quality (change: ‑0.43±0.83, p Disclosure K. K. Hood: Consultant; Self; Cecelia Health, Cercacor, LifeScan Diabetes Institute. W. H. Polonsky: Advisory Panel; Self; Intarcia Therapeutics, Inc., Consultant; Self; Abbott Diabetes, ADOCIA, Boehringer Ingelheim Pharmaceuticals, Inc., Dexcom, Inc., Insulet Corporation, Lilly Diabetes, Novo Nordisk, Onduo LLC., Sanofi US. S. A. Macleish: Advisory Panel; Self; Insulet Corporation. C. J. Levy: Advisory Panel; Self; Dexcom, Inc., Eli Lilly and Company, Employee; Spouse/Partner; AbbVie Inc., Other Relationship; Self; Dexcom, Inc., Research Support; Self; Abbott Diabetes, Dexcom, Inc., Insulet Corporation, Tandem Diabetes Care. L. M. Huyett: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. Vienneau: Employee; Self; Insulet Corporation, Stock/Shareholder; Self; Insulet Corporation. T. T. Ly: Employee; Self; Insulet Corporation. Funding Insulet Corporation